Dr Jane Wolstenholme
BA(Hons), MSc, PhD
Associate Professor of Health Economics
I have over 25 years of experience in conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. I have been a health economist at HERC since 1998, prior to that a research associate at the University of Nottingham.
My research programme has focused on the health economics of cancer, with current research on trial-based evaluations and methodology related to prostate, breast and head and neck cancer. Previous published research relates to the economic evaluation of interventions for prostate, breast, cervical and lung cancer.
My main research interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. I am principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care and in-vitro diagnostics.
I am a health economics adviser for the NIHR RDS South Central and the lead health economist for the NIHR Community Healthcare Medtech and In Vitro Diagnostics Co-operative, Oxford University.
I supervise MSc and DPhil students. Examples of current doctoral research:
- Exploring the cost-effectiveness of chronic disease prevention strategies using local area chronic disease scenario modelling.
- Developing a modelling framework for providing individualised estimates of comparative outcomes and cost-effectiveness for competing radiotherapy technologies in cancer patients.
I have published widely and I’m co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Survival, dependency and health-related quality of life in patients with ruptured intracranial aneurysm: ten-year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT)
HUA X. et al, (2020), Neurosurgery
Improving outcomes for women diagnosed with early breast cancer through Adherence to adjuvant endocrine therapy (SWEET)
Sharp L. et al, (2020), BREAST CANCER RESEARCH AND TREATMENT, 180, 544 - 545
Quality of life in the FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised trials of selective internal radiotherapy for metastatic colorectal cancer
WOLSTENHOLME J. et al, (2019), International Journal of Cancer
The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial.
Harvie M. et al, (2019), Br J Cancer
Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMEtime CE model validation using the AdViSHE tool.
Briggs A. et al, (2019), BMC Health Services Research